TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$81 Million


Follow-on Offering

Bookrunner, September 2020


NuCana plc is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying the Company’s phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. Utilizing its’ proprietary ProTide technology, the Company is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s most advanced ProTide product candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-flouraouracil, respectively, two widely used chemotherapy agents.